APS : Aptose Biosciences Inc Stock Profile

Last Updated: 3/12/2024 0:47:16

Aptose Biosciences Inc trades with the ticker APS on the TSX and is in the Biotechnology industry.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Looking to invest in Aptose Biosciences Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.

APS.TO Stock Price and Key Stats

ETF Key Stats

Exchange: TSX

Market Cap : $33.927MM

PE Ratio:

Price: 2.09 (Updated: 3/12/2024 0:47:16)

Aptose Biosciences Inc (APS) vs Competitors in Biotechnology

Lets see how APS.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:

Aeterna Zentaris Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, IMV Inc, Intellipharmaceutics International Inc


Biotechnology Industry Comparisons

Company Market Cap ($MM) P/E Ratio EV/EBITDA Dividend Yield
Aeterna Zentaris Inc (AEZS) $12.674 N/A 1.709 N/A%
Aptose Biosciences Inc (APS) $33.927 N/A -0.231 N/A%
BELLUS Health Inc (BLU) $2,470.298 N/A -16.428 0.0%
Fennec Pharmaceuticals Inc (FRX) $352.565 N/A -21.793 N/A%
IMV Inc (IMV) $13.117 N/A -0.843 0.0%

EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield  

Comparisons within Biotechnology

  • Aptose Biosciences Inc (APS) vs Aeterna Zentaris Inc (AEZS)
    • AEZS has higher EPS (-6.47 vs -10.45). AEZS and APS both have P/E’s under 0.
  • Aptose Biosciences Inc (APS) vs BELLUS Health Inc (BLU)
    • BLU has higher EPS (-0.96 vs -10.45). BLU provides dividends, while APS does not. BLU and APS both have P/E’s under 0.
  • Aptose Biosciences Inc (APS) vs Fennec Pharmaceuticals Inc (FRX)
    • FRX has higher EPS (-1.01 vs -10.45). FRX and APS both have P/E’s under 0.
  • Aptose Biosciences Inc (APS) vs IMV Inc (IMV)
    • IMV has higher EPS (-6.11 vs -10.45). IMV provides dividends, while APS does not. IMV and APS both have P/E’s under 0.
  • Aptose Biosciences Inc (APS) vs Intellipharmaceutics International Inc (IPCI)
    • IPCI has higher EPS (-0.12 vs -10.45). IPCI and APS both have P/E’s under 0.

Our Recommendation: Hold
Shows positive EPS growth from this year to next, suggesting improving profitability.

How to Buy APS stock on the TSX

You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:

ImageProduct TitleFeaturesPrice
Editor's Choice
Wealthsimple Trade

Wealthsimple Trade

  • ETF buys and sells have $0 trading fees
  • Desktop and mobile trading
  • Reputable Brand
  • Beautiful Design
Get $25 Signup Bonus
Reliable Pick


  • ETF buys have $0 trading fees
  • Desktop and mobile trading
  • Most types of accounts available
Get $50 Free Stock Trades
Photo of author
Author Bio - Qayyum Rajan is a CFA Charterholder with 10+ years of finance experience and the co-creator of Wealthawesome.com. He has previously worked as a portfolio manager at RBC Dominion Securities and other roles at asset managers like Sentry Investments. He then started building websites and fintech apps to bring finance to everyone.

Check Out These Posts:

Leave a Comment